After observing that autophagy is selectively upregulated following 2-DG treatment in stem cell-like tumor subpopulations with high basal glycolytic activity, we wished to further characterize the role of autophagy in maintaining stemness and growth of CD133/PROM1HIGH patient-derived cells. This evidence concerns the gene PROM1 and neoplasm.